| 1 |
Xu LP, Wu DP, Han MZ, et al. A review of hematopoietic cell transplantation in China: data and trends during 2008-2016[J]. Bone Marrow Transplant, 2017, 52(11): 1512-1518.
|
| 2 |
Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology[J]. J Hematol Oncol, 2018, 11(1): 33.
|
| 3 |
Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease[J]. Blood, 2015，125(4): 606-615.
|
| 4 |
Gonzalez RM, Pidala J. Evolving therapeutic options for chronic graft-versus-host disease[J]. Pharmacotherapy, 2020, 40(8): 756-772.
|
| 5 |
Hamilton BK, Rybicki L, Arai S, et al. Association of socioeconomic status with chronic graft-versus-host disease outcomes[J]. Biol Blood Marrow Transplant, 2018, 24(2): 393-399.
|
| 6 |
El-Jawahri A, Pidala J, Khera N, et al. Impact of psychological distress on quality of life, functional status, and survival in patients with chronic graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2018, 24(11): 2285-2292.
|
| 7 |
Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅰ. diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2005, 11(12): 945-956.
|
| 8 |
Martin PJ, Lee SJ, Przepiorka D, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅵ. the 2014 clinical trial design working group report[J]. Biol Blood Marrow Transplant, 2015, 21(8): 1343-1359.
|
| 9 |
Young JS, Wu T, Chen Y, et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease[J]. J Immunol, 2012, 189(1): 222-233.
|
| 10 |
Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease[J]. Biol Blood Marrow Transplant, 2017, 23(2): 211-234.
|
| 11 |
Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease[J]. Nat Med, 2012, 18(7): 1028-1040.
|
| 12 |
Macdonald KPA, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies[J]. Blood, 2017, 129(1): 13-21.
|
| 13 |
Dubovsky JA, Flynn R, Du J, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease[J]. J Clin Invest, 2014, 124(11): 4867-4876.
|
| 14 |
Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes[J]. Blood, 2013, 122(15): 2539-2549.
|
| 15 |
Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765[J]. Blood, 2011, 117(23): 6287-6296.
|
| 16 |
Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD[J]. Blood Adv, 2018, 2(5): 2012-2019.
|
| 17 |
Srinivasan M, Flynn R, Price A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans[J]. Blood, 2012, 119(6): 1570-1580.
|
| 18 |
Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease[J]. Haematologica, 2008, 93(11): 1702-1711.
|
| 19 |
Ryan CE, Sahaf B, Logan AC, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT[J]. Blood, 2016, 128(26): 2899-2908.
|
| 20 |
Schutt SD, Fu J, Nguyen H, et al. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice[J]. PLoS One, 2015, 10(9): e0137641.
|
| 21 |
Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy[J]. Blood, 2017, 130(21): 2243-2250.
|
| 22 |
Waller EK, Miklos D, Cutler C, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b/2 study[J]. Biol Blood Marrow Transplant, 2019, 25(10): 2002-2007.
|
| 23 |
Miklos DB, Jagasia MH, Greinix H, et al. A randomized, double-blind phase Ⅲ study of ibrutinib versus placebo in combination with corticosteroids in patients with new onset chronic graft versus host disease[J]. J Clin Oncol, 2017, 35(15_suppl): TPS7072-TPS7072.
|
| 24 |
Teusink-Cross A, Davies SM, Grimley MS, et al. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience[J]. Pediatr Transplant, 2020, 24(6): e13692.
|